Navigation Links
Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
Date:1/7/2008

CALGARY, Jan. 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled "Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus" appears online in the January 1, 2008 issue of Clinical Cancer Research.

"This exciting Mayo Clinic work supported the initiation of our combination REOLYSIN(R) and cyclophosphamide clinical trial, recently approved by the U.K. health authorities," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

The purpose of the research study was to investigate whether it was possible to use cyclophosphamide, an immune modulator, to enhance the delivery and replication of the reovirus when delivered intravenously. After testing various doses and dosing regimens of reovirus and cyclophosphamide in mice, a metronomic dosing regimen was developed that resulted in increased survival, high levels of reovirus recovered from regressing tumors, levels of neutralizing antibodies that were protective, and only very mild toxicities. The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the immune system.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
...is. - Marshfield Clinic has reached an agreem...tware developed by TeraMedica , a Milwaukee-based...n as Evercore, will be deployed to integrate all o...d non-medical images, then distribute them within ...ll make them available to Marshfield Clinic,s heal...
...Baird Venture Partners , the U.S. venture fund of ... on its presence in China by partnering with the I..., to serve portfolio companies as they establish a...nterview with WTN, Paul Carbone, managing partner ...ivate Equity Group, explained the venture fund,s p...
.... - Dr. Leroy Hood, a prominent molecular biologi...f directors of NimbleGen Systems , a Madison biot...sident of the Seattle-based Institute for Systems...cientific advisory board. , ,A former professor a...ia Institute of Technology , Hood gained notoriety...
Other Biology Technology:Visions: Carbone bullish on Wisconsin venture capital 2Visions: Carbone bullish on Wisconsin venture capital 3Visions: Carbone bullish on Wisconsin venture capital 4Visions: Carbone bullish on Wisconsin venture capital 5
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Acculturation affects smoking cessation success among Latinos 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Introducing All New IEHP Superhero to Battle Childhood Obesity 54248 1Introducing All New IEHP Superhero to Battle Childhood Obesity 54248 2Introducing All New IEHP Superhero to Battle Childhood Obesity 54248 3PA Department of Health Confirms the First Human Case of West Nile Virus in Pennsylvania for 2009 54244 1PA Department of Health Confirms the First Human Case of West Nile Virus in Pennsylvania for 2009 54244 2PA Department of Health Confirms the First Human Case of West Nile Virus in Pennsylvania for 2009 54244 3Mediterranean Diet Plus Exercise Lowers Alzheimers Risk 54241 1Mediterranean Diet Plus Exercise Lowers Alzheimers Risk 54241 2Mediterranean Diet Plus Exercise Lowers Alzheimers Risk 54241 3
...large portion of plant seeds is endosperm. It has ...during the early stages of its development. In flo...lisation mechanism that arises among embryos and e...ds. The exact process, and the communication betwe... scientists. Researchers at the Max Planck Institu...
...e INVORAD project developed systems for real-time ...nsity Modulated Radiotherapy (IMRT). IMRT is a rad...outcomes by more accurately targeting tumours and ...lthy tissue. , The result is that patients only re... healthy tissue is preserved. , The problem with ...
...e Johns Hopkins scientists who first created "migh...ny Wyeth and the biotechnology firm MetaMorphix, a... mass in mice than a related potential treatment f...e new agent is a version of a cellular docking poi...ice, just two weekly injections of the new agent t...
Other Biology News:The secret love life of plants 2Sensors, a smart dose of medicine for cancer treatment 2Sensors, a smart dose of medicine for cancer treatment 3Mouse study: New muscle-building agent beats all previous ones 2
Benchtop Laminar Flow Hood (Environmental Control Module) from Terra Universal, Inc.
SlideHyb Glass Array Hybridization Buffer #1 from Ambion
Denhardt's powder mixture (for 50X stock solution) from AppliChem GmbH
...Mixes are optimised for SYBR Green I assays and co...titative PCR, with the exception of template and p...l levels of active SYBR Green I dye and Thermo-Sta...on buffer that enables detection of low copy numbe...
Biology Products: